LncRNA TYMSOS is a novel prognostic biomarker and associated with immune infiltration in prostate cancer

Abstract

LncRNA TYMSOS plays an important role in cancers; However, its impact on prostate cancer (PCa) is still unclear. Thus, we analyzed the relationship between TYMSOS expression and PCa using the data from The Cancer Genome Atlas (TCGA) TCGA and Genotype Tissue-Expression (GTEx). Wilcoxon rank serum test and logistic regression were used to compare TYMSOS expression in PCa and normal tissues, and evaluated its correlation with clinicopathological features. Receiver operating characteristic (ROC) curves was used to evaluate the prediction accuracy of TYMSOS. Correlation between TYMSOS expression and prognosis was evaluated using Kaplan-Meier analysis and Cox regression. Gene Set Enrichment Analysis (GSEA), Gene Set Variation Analysis (GSVA) and ImmuCellAI platform were performed to determine biological function, signal pathways, and immune cell infiltration for TYMSOS in PCa. By analyzing the online data, we found that TYMSOS was highly expressed in PCa and associated with T stage , Gleason score, age, and primary therapy outcome. The results of ROC curve showed that TYMSOS has a significant diagnostic ability. Furthermore, Kaplan-Meier analyses suggested that TYMSOS plays an important role in progression-free survival (PFS). Increased TYMSOS expression was an independent risk factor correlated with PFS in PCa patients. GSEA and GSVA indicated that TYMSOS was involved in cell cycles, neurodegenerative diseases, oxidative phosphorylation, spliceosomes, and adaptive immune system pathways. Additionally, TYMSOS expression was also associated with immune cell infiltrates and tumor mutational burden in PCa. The functional experiments were further conducted, and we verified that TYMSOS played an oncogenic role in regulating PCa aggressiveness. Specifically, silencing of TYMSOS suppressed cell proliferation, division and epithelial-mesenchymal transition (EMT), whereas promoted cell apoptosis in the PCa cells, and conversely, TYMSOS overexpression had opposite effects. In summary, our study revealed that TYMSOS could be a biomarker and therapeutic targets in PCa and a participant in tumor-immune cell infiltration.